North America Infectious Disease Rapid Diagnostics Market Report 2025-2035 Featuring Abbott, F. Hoffmann-La Roche, Danaher, DiaSorin, Hologic, BGI, Quidel, Cellex, bioMerieux, Thermo Fisher Scientific
The North American infectious disease rapid diagnostics market is growing due to rising incidences of diseases like influenza and STIs, driving demand for fast diagnostic tests. Key technologies include molecular diagnostics and antigen tests, crucial for early detection and managing infections. The U.S. leads the market, benefiting from a robust healthcare system and regulatory support. Challenges include strict FDA regulations and high costs. Major players like Abbott and Thermo Fisher are innovating to meet rising demands for effective, rapid diagnostics.
Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "North America Infectious Disease Rapid Diagnostics Market - A Regional Analysis: Focus on Product, Technology, Application, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.Infectious Disease Rapid Diagnostics are tests designed to quickly detect and identify infectious agents such as bacteria, viruses, or fungi, enabling fast treatment decisions. These tests provide results in minutes to a few hours, crucial for early detection and effective management of infections. They include molecular diagnostics, antigen tests, and serological assays for diseases such as influenza, COVID-19, and STIs.The increasing incidence of infectious diseases such as influenza, sexually transmitted infections (STIs), respiratory infections, and hospital-acquired infections (HAIs) is a major driver of the North American rapid diagnostics market. For instance, the CDC reported in 2023 that the U.S. experienced an uptick in flu cases, with over 15 million cases reported that year, emphasizing the need for fast and efficient diagnostic tests. The growing threat of antimicrobial resistance (AMR) and the emergence of novel pathogens, such as the resurgence of multidrug-resistant tuberculosis and the rise of drug-resistant gonorrhea, have made early and accurate disease detection more critical than ever to control outbreaks and prevent further resistance.Moreover, governments and healthcare organizations are heavily investing in rapid testing solutions to enhance early disease detection and control outbreaks. During the 2023 influenza season, the U.S. government expanded the use of Quidel's Sofia 2 SARS Antigen FIA test for quick identification of flu and COVID-19 co-infections in emergency departments. The demand for point-of-care (POC) diagnostics in emergency settings, outpatient clinics, and remote locations has risen as healthcare systems strive to reduce diagnostic turnaround times and improve patient outcomes. For instance, the Abbott ID NOW molecular diagnostic system has been deployed widely in rural and remote areas to quickly detect respiratory infections such as flu and COVID-19, providing results in just 15 minutes.A significant opportunity in the North American rapid diagnostics market lies in the expansion of point-of-care testing (POCT) across decentralized healthcare settings, such as pharmacies, urgent care centers, and home-based testing. The rising demand for fast, reliable, and affordable diagnostics outside of traditional hospital environments is opening new growth avenues for diagnostic companies. With growing government support and increasing regulatory approvals for POCT, the adoption of portable diagnostic devices is expected to surge, particularly for diseases like STIs, respiratory infections, and gastrointestinal infections.However, the major challenges faced by the North America infectious disease rapid diagnostics market are the stringent regulatory framework and pricing constraints. The FDA approval process for new diagnostic tests can be time-consuming and complex, delaying product launches and market entry. For instance, Cepheid's Xpert Xpress COVID-19 test, while highly effective, faced regulatory hurdles and delays before it received Emergency Use Authorization (EUA) in 2020. The approval process for new technologies can extend product launch timelines, delaying access to critical diagnostics.Additionally, the high cost of advanced molecular diagnostic technologies such as q-PCR and INAAT makes them less accessible, particularly in resource-limited settings. Although reimbursement policies are improving, inconsistent insurance coverage for rapid diagnostic tests remains a barrier to widespread adoption. A study published by the National Institutes of Health (NIH) found that the cost of a single qPCR test for COVID-19 could range from $100 to $200, limiting accessibility in smaller clinics or remote healthcare settings.Pricing pressures also arise due to competition from generic or low-cost diagnostic alternatives, especially in non-hospital settings. Moreover, healthcare providers are often hesitant to adopt new diagnostic technologies without clear cost-effectiveness data or strong clinical validation. These regulatory and pricing challenges could slow market growth and limit accessibility to cutting-edge diagnostic solutions.Key market players in the North American infectious disease rapid diagnostics market are focusing on innovation, strategic partnerships, and expanding product offerings to meet the growing demand for faster, more accurate testing solutions. For instance, in April 2022, Thermo Fisher Scientific, Inc. launched the TaqPath COVID-19 RNase P 2.0 Assay Kit, designed to detect SARS-CoV-2, including emerging variants.Key players in the market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, DiaSorin S.p.A, Hologic, Inc., BGI Group,Quidel Corporation, Cellex,bioMerieux S.A., and Thermo Fisher Scientific Inc., etc.
Assay to Lead the Infectious Disease Rapid Diagnostics MarketAssays dominate the North America infectious disease rapid diagnostics market due to their widespread applicability, affordability, and efficiency in detecting a range of infectious diseases. Assays, including immunoassays and molecular assays, are used extensively in hospitals, clinics, and point-of-care (POC) settings for rapid disease detection, enabling timely treatment decisions. Their cost-effectiveness compared to fully automated diagnostic systems makes them accessible to a broader range of healthcare providers.With the rising prevalence of infectious diseases such as respiratory infections, sexually transmitted infections (STIs), and gastrointestinal infections, demand for rapid and accurate diagnostic assays is increasing. Advances in multiplex assays, capable of detecting multiple pathogens from a single sample, further enhance their clinical value. Additionally, regulatory approvals for at-home diagnostic assays, particularly for diseases like COVID-19 and influenza, are expected to drive market expansion. As a result, assays remain a cornerstone of infectious disease diagnostics.
Real-Time Polymerase Chain Reaction (q-PCR) to Lead the Infectious Disease Rapid Diagnostics MarketReal-Time Polymerase Chain Reaction (q-PCR) is projected to be the dominant technology in the North America infectious disease rapid diagnostics market due to its high sensitivity, specificity, and rapid turnaround time. q-PCR is widely used for detecting viral and bacterial infections, particularly in hospital laboratories and reference labs where accuracy is crucial for clinical decision-making.One key advantage of q-PCR is its ability to quantify pathogen load, enabling physicians to monitor disease progression and treatment effectiveness. The increasing incidence of respiratory infections (e.g., COVID-19, influenza, RSV) has led to widespread adoption of q-PCR tests. Moreover, innovations in portable and automated q-PCR devices are expanding the technology's usability in point-of-care (POC) and decentralized settings.With ongoing advancements in multiplex PCR assays, which allow simultaneous detection of multiple pathogens, q-PCR will continue to be the gold standard for rapid, high-accuracy infectious disease diagnostics.U.S. Region to Lead the North America Infectious Disease Rapid Diagnostics Market (by Country)The U.S. is expected to lead the North America infectious disease rapid diagnostics market throughout the forecast period due to several key factors. The country has a high prevalence of infectious diseases, such as respiratory, gastrointestinal, and sexually transmitted infections, which drives the demand for rapid diagnostic solutions.
The U.S. also boasts a robust healthcare infrastructure with well-established hospitals, diagnostic centers, and research institutions that promote the adoption of innovative diagnostic technologies. Regulatory support from the FDA, including expedited approval pathways, allows faster market entry for new diagnostic products, further fueling growth.
Additionally, increased investments from government initiatives, private sector funding, and collaborations between biotech companies and academic institutions are boosting R&D in rapid diagnostics. The U.S. remains at the forefront of adopting advanced diagnostic technologies, including molecular diagnostic platforms, AI-driven tools, and portable rapid test kits. While Canada experiences steady growth, the U.S. will continue to be the primary driver of market expansion in the region.
Key Topics Covered:1. Markets: Industry Outlook1.1 Trends: Current and Future Impact Assessment1.2 R&D Review1.2.1 Patent Filing Trend by Year1.3 Regulatory Landscape1.4 Market Dynamics1.4.1 Market Drivers1.4.2 Market Restraints1.4.3 Market Opportunities2. North America Infectious Disease Rapid Diagnostic Market (by Product)2.1 Assays2.2 Platforms3. North America Infectious Disease Rapid Diagnostic Market (by Technology)3.1 Real-Time PCR (q-PCR)3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)3.3 Others4. North America Infectious Disease Rapid Diagnostic Market (by Application)4.1 Respiratory Infection4.2 Gastro-Intestinal Infection4.3 Hospital Acquired Infection4.4 Sexually Transmitted Infections4.5 Others5. North America Infectious Disease Rapid Diagnostic Market (by Country)5.1 U.S5.2 Canada6. Competitive Landscape and Company Profiles 6.1 Key Strategies and Developments6.1.1 Product Approvals6.1.2 Product Launches and Upgradations6.1.3 Synergistic Activities6.1.4 Funding and Expansion6.1.5 Mergers and Acquisitions6.2 Company Profiles6.2.1 Company Overview6.2.2 Product Portfolio6.2.3 Top Competitors6.2.4 Analyst View
Abbott Laboratories
F. Hoffmann-La Roche Ltd
Danaher Corporation
DiaSorin S.p.A
Hologic, Inc.
BGI Group
Quidel Corporation
Cellex
bioMerieux S.A.
Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/72bhhs
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Hundreds of people raise $84,000 for Pulmonary Fibrosis Foundation during annual walk in Pittsburgh
Hundreds of people gathered in Pittsburgh's Riverfront Park on Saturday for the Pulmonary Fibrosis Foundation's annual walk. Participants walked on a one or two-mile course in support of those living with pulmonary fibrosis, a group of progressive lung diseases that cause scarring in the lungs, which limits oxygen intake necessary for major organs to function. Pulmonary fibrosis currently affects more than 250,000 Americans, and 50,000 new cases are diagnosed each year, according to PFF. Organizers say individuals and teams from the Pittsburgh region raised more than $84,000 to advance research for a cure for the life-threatening disease. Download the FREE WPXI News app for breaking news alerts. Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Yahoo
an hour ago
- Yahoo
Campus notes: June 22, 2025
Teagan Graham, Reading, graduated from the University at Buffalo, N.Y., with a bachelor's degree in health and human services/early childhood education. York College The following area students received degrees from York College of Pennsylvania: Master of education: Julianna Kusy, Kutztown; Isabelle Popoter, Spring Township. Master of science in nursing: Elyse Batson, Exeter Township. Bachelor of arts: Isabella Antos, South Heidelberg Township; Lauryn Johnson, Exeter Township; Isabella Hoeltzel, Leesport; Elizabeth Trumbore, Temple. Bachelor of business administration: Gabriel Trevena, South Heidelberg Township. Bachelor of science: Brett Reinert, Douglassville; Haley Akins, Markus Jeschonnek and Brianna Endy, Exeter Township; Alexander LaVerdure, Oley Township;. Bachelor of science in nursing: Morgan Sauers, Gilbertsville; Taryn Boyer, Temple. Items are supplied by the colleges involved.
Yahoo
2 hours ago
- Yahoo
What's the difference between an extreme heat watch and warning?
States across the Central and Eastern U.S. are under extreme heat watches and warnings as the areas are facing "dangerous heat," according to the National Weather Service. "Though record high temperatures are expected in the coming days, the duration of the heat, as demonstrated by the numerous record warm morning lows, will make this period especially oppressive," the National Weather Service posted on X June 20. The weather service has issued extreme heat warnings for areas in over a dozen states, as they face the highest temperatures of the year so far. It also issued extreme heat watches in several states and Washington D.C., according to an advisory issued to the agency's website. Here's everything you need to know about the heat wave. Portions of the following states have been placed under an extreme heat warning, according to the National Weather Service: Indiana Iowa Massachusetts Michigan Minnesota Missouri Nebraska New York Ohio Pennsylvania Rhode Island South Dakota Vermont West Virginia Areas where dangerous heat is possible are placed under an extreme heat warning and are asked to prepare in case it happens. Areas where dangerous heat "is happening or about to happen" are placed under an extreme heat warning, according to the weather service. While areas that are placed on a watch are asked to reschedule any planned outdoor activities, people in areas placed under warnings are told to avoid any heavy activity and direct sunlight. People facing extreme heat should do the following, according to NWS: Drink plenty of fluids Stay in an air-conditioned room Stay out of the sun Check up on relatives and neighbors Do not leave young children and pets in unattended vehicles Wear lightweight and loose-fitting clothing outdoors Limit strenuous activities to early morning or evening The extreme heat could negatively impact people's health. "Heat-related illnesses increase significantly during extreme heat and high humidity events," according to the National Weather Service. The following factors increase the possibility of a heat-related illness, according to the National Park Service: High humidity High elevation Strenuous activity Age: Infants, young children and people over 65 are more susceptible to heat illness Pregnancy Obesity Heart disease Poor circulation Fever Mental illness Dehydration Sunburn Prescription drug and alcohol use There are multiple forms of heat illnesses, but heatstroke is the deadliest and most dangerous, according to the NPS. The following are symptoms of heatstroke, according to the Centers for Disease Control and Prevention: Body temperature of 103 degrees or higher Skins that is hot, red, dry or damp Fast, strong pulse Headache Dizziness Nausea Confusion Losing consciousness In the case of a heatstroke, the CDC recommends people do the following: Call 911 immediately Move the person suffering from heatstroke to a cool location Lower the person's body temperature with a cool cloth or bath Do not give the person suffering from a heatstroke water or anything to drink Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram and TikTok: @juliamariegz, or email her at jgomez@ This article originally appeared on USA TODAY: What's the difference between an extreme heat watch and warning?
